ArticleNucleic acids research2024
ncRNADrug: a database for validated and predicted ncRNAs associated with drug resistance and targeted by drugs.
Article in Nucleic acids research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 45 citations in OpenAlex.
- MDCL: Multi-source Information Fusion and Collaborative Contrastive Learning for Inferring miRNA-Drug Sensitivity and Resistance Associations.Interdisciplinary sciences, computational life sciences · 2026Article
- An integrative multi-omics modeling framework for chemotherapy response prediction through microRNA-target regulatory signatures.Briefings in bioinformatics · 2026Article
- Predicting circRNA-Drug Sensitivity Using Integrated Hybrid Graph and Molecular Features.Interdisciplinary sciences, computational life sciences · 2026Article
- Targeting non-coding RNAs in the ferroptosis system: Molecular mechanisms and clinical translation for reversing doxorubicin resistance in breast cancer.Non-coding RNA research · 2026Review
- Heterogeneous dual-channel and interpretable graph representation learning with global virtual nodes for microRNA-mediated drug sensitivity prediction.Molecular diversity · 2026Article
- MIFNDRA: an innovative knowledge-enhanced multimodal fusion and graph learning framework for predicting drug resistance-related ncRNAs.Briefings in bioinformatics · 2026Article
- A pre-trained language model-based cross-modal fusion framework for predicting miRNA-drug resistance and sensitivity associations.PLoS computational biology · 2026Article
- MPHGNN: metapath-guided heterogeneous graph neural network for miRNA-drug resistance association prediction.Briefings in bioinformatics · 2026Article
- EVmiRNA2.0: an updated database for miRNA expression in comprehensive human extracellular vesicles.Nucleic acids research · 2026Article
- Semantic-enhanced heterogeneous graph learning for identifying ncRNAs associated with drug resistance.Bioinformatics (Oxford, England) · 2026Article
- Regulation of the Wnt/β-Catenin Signaling Pathway by Non-Coding RNAs in Esophageal Squamous Cell Carcinoma: Mechanisms, Translational Relevance, and Therapeutic Implications.Oncology research · 2026Review
- Leveraging 3D Molecular Spatial Visual Information and Multi-Perspective Representations for Drug Discovery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- AutoML identification of microRNA biomarkers in high-risk pediatric acute lymphoblastic leukemia.Non-coding RNA research · 2025Article
- Integrated bioinformatics and deep learning (MLP) approach reveals a novel five miRNA prognostic signature in uveal melanoma.Scientific reports · 2025Article
- Multi-view fusion based on graph convolutional network with attention mechanism for predicting miRNA related to drugs.PLoS computational biology · 2025Article
- Proceedings of cell-free noncoding RNA biomarker studies in liquid biopsy.Rheumatology and immunology research · 2025Article
- Machine learning approaches for predicting the small molecule-miRNA associations: a comprehensive review.Molecular diversity · 2025Review
- Review
- The Potential Role of Egg-Derived Xeno-miRs in Chemotherapy Response: An In Silico Approach.Food science & nutrition · 2025Article
- Emerging artificial intelligence-driven precision therapies in tumor drug resistance: recent advances, opportunities, and challenges.Molecular cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
Drug resistance is a major barrier in cancer treatment and anticancer drug development. Growing evidence indicates that non-coding RNAs (ncRNAs), especially microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), play pivotal roles in cancer progression, therapy, and drug resistance. Furthermore, ncRNAs have been proven to be promising novel therapeutic targets for cancer treatment. Reversing dysregulated ncRNAs by drugs holds significant potential as an effective therapeutic strategy for overcoming drug resistance. Therefore, we developed ncRNADrug, an integrated and comprehensive resource that records manually curated and computationally predicted ncRNAs associated with drug resistance, ncRNAs targeted by drugs, as well as potential drug combinations for the treatment of resistant cancer. Currently, ncRNADrug collects 29 551 experimentally validated entries involving 9195 ncRNAs (2248 miRNAs, 4145 lncRNAs and 2802 circRNAs) associated with the drug resistance of 266 drugs, and 32 969 entries involving 10 480 ncRNAs (4338 miRNAs, 6087 lncRNAs and 55 circRNAs) targeted by 965 drugs. In addition, ncRNADrug also contains associations between ncRNAs and drugs predicted from ncRNA expression profiles by differential expression analysis. Altogether, ncRNADrug surpasses the existing related databases in both data volume and functionality. It will be a useful resource for drug development and cancer treatment. ncRNADrug is available at http://www.jianglab.cn/ncRNADrug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.